ARCHIVES

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

This article is from The Cancer Letter archive.

Vol. 27 No. 09 | March 2, 2001

Download PDF Visit The Full Archive

Related Articles

FDA Approves Ixempra For Metastatic Breast Cancer Resistant To Other Therapy

October 26, 2007

Center Directors Solidly opposed To Core grant changes, Ask Upton, NCAB To Find Other Solutions

November 11, 1977

Attempt To Push NCI To Establish Diagnostic Coordinating Group Fails

July 5, 1974

ASCO Proposes Principles For Future Debate on Medicaid

November 21, 2014

In Brief: Trials Find DiBella Treatment Ineffective; Wistar Wins $1 Million Grant For Recruitment

December 4, 1998

NCI-Approved Clinical Trials Listed For January

January 28, 2005